We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Rheumatology

Journal Scan / Research · December 06, 2022

Anti-CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus

Nature Medicine


Additional Info

Nature Medicine
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
Nat. Med. 2022 Oct 01;28(10)2124-2132, A Mackensen, F Müller, D Mougiakakos, S Böltz, A Wilhelm, M Aigner, S Völkl, D Simon, A Kleyer, L Munoz, S Kretschmann, S Kharboutli, R Gary, H Reimann, W Rösler, S Uderhardt, H Bang, M Herrmann, AB Ekici, C Buettner, KM Habenicht, TH Winkler, G Krönke, G Schett

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading